Monopar Therapeutics's EBIT per Share for the
three
months ended in Mar. 2024 was $-0.11.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.56.
During the past 3 years, the average EBIT per Share Growth Rate was -2.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -16.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Monopar Therapeutics's EBIT per Share or its related term are showing as below:
MNPR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -59.7 Med: -21.3 Max: 28
Current: -2.5
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Monopar Therapeutics was 28.00% per year. The lowest was -59.70% per year. And the median was -21.30% per year.
MNPR's 3-Year EBIT Growth Rate is ranked worse than 56.78% of 1305
companies
in the Biotechnology industry
Industry Median: 3.4
vs MNPR: -2.50
Monopar Therapeutics EBIT per Share Historical Data
The historical data trend for Monopar Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics (NAS:MNPR) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Monopar Therapeutics EBIT per Share Related Terms
Thank you for viewing the detailed overview of Monopar Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Monopar Therapeutics (Monopar Therapeutics) Business Description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MNPR has been successfully added to your 